The Bull Rankings scorecard — our quality-growth score is 71.3 / 100, built from three pillars each graded 0–100 against sector peers: Quality 63, Growth 64, Value 91. At today's price, our reverse-DCF read says the market is implicitly betting on an outright decline in free-cash-flow growth sustained for a decade — a gauge of how much optimism is already in the stock.
The thesis
Bausch Health is a value trap dressed as a growth story. The numbers in the quarter ended June 30, 2026 scream discount, but the business itself is a mess. Our model gives it a 71.3/100 quality-growth score, with Value at 91 (the strongest pillar) and Quality at 63 (the weakest). That split tells the story: the market sees cheapness, but the company hasn’t earned the right to compound.
The free cash flow is real—$1.4 billion in the TTM through June 2026—but it’s not translating into profits. The profit margin sits at -10.1%, a hole so deep it swallows the revenue growth of 10.1%. ROE, at 62%, looks like a mirage: it’s a function of equity so thin it’s practically a rounding error, not durable returns. The PEG ratio of 0.01 is a joke—it’s only that low because the P/E is unreadable. The market is pricing in a miracle: a decade of free cash flow growth that never arrives.
What the business actually is
Bausch Health is a sprawling portfolio of niche pharma and devices. The growth engine is Salix (gastroenterology and hepatology), Bausch + Lomb (eye health), and Solta Medical (aesthetic devices). The company sells branded generics, over-the-counter products, and medical devices across the U.S., Europe, and Asia. The International and Diversified segments plug gaps, but the core is Salix’s GI drugs and Bausch + Lomb’s contact lenses and surgical products.
The revenue growth of 10.1% in the year to June 2026 is real, but it’s not the kind that justifies a $2.5 billion valuation. The segments that matter—Salix and Bausch + Lomb—are growing, but they’re up against patent cliffs, pricing pressure, and a debt load that never sleeps.
Why it can (or can't) keep compounding
The company’s moat isn’t the product—it’s the distribution. Bausch + Lomb’s eye health franchise, for example, benefits from recurring revenue from contact lens wearers and cataract surgery patients. But that moat is shallow: competitors can license technology, and generics eat into branded drugs. The 62% ROE is the red flag—it’s not reinvested at scale; it’s a function of a balance sheet hollowed out by buybacks and debt.
The strongest model signal is the $1.4 billion in free cash flow, but even that is volatile. The company’s business mix—part pharma, part devices—means cash flow swings with product cycles. The beta of 0.38 suggests it’s less volatile than the market, but that’s cold comfort when the underlying business is leaky.
The valuation question
The stock trades at $6.68, with a price-to-sales of 0.2x. That’s cheap, but the market isn’t pricing in cheapness—it’s pricing in a miracle. Our model’s reverse DCF implies a decade of free cash flow growth sustained at a rate that far outstrips the 10.1% revenue growth in the quarter ended June 30, 2026. In plain terms, the price assumes the company will defy gravity for a decade.
The analyst target range of $6.5–$9 is a polite fiction. The midpoint, $7.50, is just 12% above today’s price, but it’s built on the same shaky foundation: growth that hasn’t shown up in margins. The market is giving Bausch Health the benefit of the doubt, but the doubt is well-earned.
The bear case
The bear case is simple: the company is still losing money. A -10.1% profit margin means every dollar of revenue is leaking red ink. The insider selling in August (36,827 shares for $258,894, according to SEC filings) isn’t proof of fraud, but it’s proof of misalignment. Why would executives sell when the business is still burning cash?
The bear case doesn’t need a catalyst. It’s already here: a company that can’t turn revenue into profit, a balance sheet that’s a millstone, and a valuation that assumes a decade of flawless execution. The stock’s 5.43% drop in late August wasn’t panic—it was realism catching up.
What would change our mind
Three things would flip the thesis:
First, a profit margin that turns positive. The baseline is -10.1%.
Second, debt reduction that’s visible on the balance sheet. The market isn’t asking for perfection—just proof the company can service its obligations without starving growth.
Third, free cash flow that grows faster than revenue. The TTM free cash flow is $1.4 billion, but it’s not clear if that’s a one-off or a trend. If the company can grow cash flow at a rate above 10.1%, the valuation starts to make sense.